Silence Therapeutics Announces Publication in Cardiovascular Research Highlighting the Emerging Potential of RNA Therapeutics in Preventing Lipoprotein(a)-Mediated Cardiovascular Disease
April 15, 2021 07:00 ET
|
Silence Therapeutics plc
Silence Therapeutics Announces Publication in Cardiovascular Research Highlighting the Emerging Potential of RNA Therapeutics in Preventing Lipoprotein(a)-Mediated Cardiovascular Disease –High...
Silence Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
April 07, 2021 07:00 ET
|
Silence Therapeutics plc
Silence Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference 7 April 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a...
Silence Therapeutics Reports Full-year 2020 Results
March 30, 2021 07:00 ET
|
Silence Therapeutics plc
Silence Therapeutics Reports Full-year 2020 ResultsAdvancing clinical programmes; On-track for three phase 1 data readouts in 2021 30 March 2021 LONDON, Silence Therapeutics plc, AIM: SLN and...
Silence Therapeutics to Present at the Barclays Global Healthcare Conference
March 04, 2021 07:00 ET
|
Silence Therapeutics plc
Silence Therapeutics to Present at the Barclays Global Healthcare Conference 4 March 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the...
Silence Therapeutics and Mallinckrodt Initiate Work on Third Target as Part of Ongoing RNAi Research Collaboration for Complement-Mediated Diseases
February 26, 2021 07:00 ET
|
Silence Therapeutics plc
Silence Therapeutics and Mallinckrodt Initiate Work on Third Target as Part of Ongoing RNAi Research Collaboration for Complement-Mediated Diseases Silence to receive $2 million research milestone...
Silence Therapeutics to Participate in March Investor Conferences
February 22, 2021 07:00 ET
|
Silence Therapeutics plc
Silence Therapeutics to Participate in March Investor Conferences 22 February 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery,...
Silence Therapeutics to Present at the 2021 SVB Leerink Global Healthcare Conference
February 18, 2021 07:00 ET
|
Silence Therapeutics plc
Silence Therapeutics to Present at the 2021 SVB Leerink Global Healthcare Conference 18 February 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a...
Silence Therapeutics Initiates Dosing in Phase 1 Clinical Trial of SLN360 for Cardiovascular Disease Due to High Lipoprotein(a)
February 17, 2021 07:00 ET
|
Silence Therapeutics plc
Silence Therapeutics Initiates Dosing in Phase 1 Clinical Trial of SLN360 for Cardiovascular Disease Due to High Lipoprotein(a) 17 February 2021 LONDON, Silence Therapeutics plc, AIM: SLN and...
Silence Therapeutics plc Announces $45 Million Private Placement
February 05, 2021 07:00 ET
|
Silence Therapeutics plc
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN...
Silence Therapeutics Appoints Michael H. Davidson, MD, to Board of Directors
January 06, 2021 07:00 ET
|
Silence Therapeutics plc
Silence Therapeutics Appoints Michael H. Davidson, MD, to Board of Directors Leading expert in lipidology to support Silence as it advances new approach to treating cardiovascular disease with lead...